The evolving role of stem cell transplants in lymphomas

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Autologous stem cell transplantation (ASCT) is a standard treatment for lymphomas, particularly in relapsed cases.
• The use of allogeneic stem cell transplantation (alloSCT) for lymphoma patients has increased, but optimal indications remain unclear.
• Advances in lymphoma treatments, including immunotherapy, impact the effectiveness of ASCT and increase interest in alloSCT.

Purpose of the Study:

• To review the current landscape of ASCT and alloSCT in lymphoma treatment.
• To discuss the evolving role of alloSCT, especially in earlier disease phases or after ASCT failure.
• To highlight the need for prospective studies to clarify alloSCT's efficacy and safety.

Main Methods:

• Review of data from the European Blood and Marrow Transplantation (EBMT) registry.
• Analysis of trends in ASCT and alloSCT for lymphoma patients.
• Discussion of clinical scenarios influenced by new lymphoma therapies and transplant outcomes.

Main Results:

• Over 6000 ASCTs for lymphomas are reported annually to the EBMT.
• Approximately 1200 alloSCTs for lymphoma patients are performed annually.
• ASCT may be less effective in patients relapsing after immunochemotherapy, driving interest in alloSCT.

Conclusions:

• AlloSCT offers higher curative potential but has been limited by nonrelapse mortality (NRM).
• Decreasing NRM may increase alloSCT's popularity, potentially at ASCT's expense.
• Randomized trials are essential to establish the feasibility and efficacy of alloSCT in various lymphoma settings.